Metabolic Status Regulates Ghrelin Function on Energy Homeostasis

Dana I. Briggs Zane B. Andrews
Department of Physiology, Monash University, Clayton, Vic., Australia

Abstract
Ghrelin plays an important role in energy metabolism by regulating food intake, body weight and glucose homeostasis. In this review, we highlight recent developments describing how ghrelin stimulates neuropeptide Y (NPY) neurons, but not pro-opiomelanocortin neurons, to regulate food intake. We describe a novel signaling modality, in which ghrelin activates NPY/agouti-related protein (AgRP) neurons through fatty acid oxidation, reactive oxygen species buffering and mitochondrial function. We hypothesize that this unique system may serve to maintain NPY/AgRP cell function during prolonged negative energy balance. We discuss the idea that the metabolic status plays a key role in ghrelin function. For example, our recent studies illustrate that diet-induced obesity causes ghrelin resistance in arcuate NPY/AgRP neurons. On the other side of the metabolic coin, ghrelin and GOAT knockout models show that ghrelin is required to maintain blood glucose during severe calorie restriction. We propose the hypothesis that ghrelin primarily functions during negative energy balance to maintain whole-body energy homeostasis.

Key Words
Neuropeptide Y • Pro-opiomelanocortin • Arcuate nucleus • Diet-induced obesity • Calorie restriction • Growth hormone secretagogue receptor • Glucose homeostasis • Food intake • Body weight regulation

Hypothalamic Regulation of Food Intake
Food intake and energy metabolism are regulated by a complex interplay between neural networks in the central nervous system and peripheral tissues. Within the central nervous system, food intake is largely controlled by a fine balance between orexigenic and anorexigenic neuropeptides in the arcuate nucleus (ARC) of the hypothalamus. Neuropeptide Y (NPY) and agouti-related protein (AgRP) are coexpressed in neurons of the ARC and are potent orexigenic peptides, whereas pro-opiomelanocortin (POMC) precursor protein in the ARC is cleaved into anorexigenic α-melanocyte-stimulating hormone (α-MSH) peptides. NPY/AgRP and POMC neurons in the ARC are arguably considered ‘first-order’ sensory neurons in the control of food intake. These neurons receive, coordinate and respond to changes in varying humoral factors, such as hormones, glucose and fatty acids, associated with different metabolic states. Both NPY/AgRP and POMC neurons project to the paraventricular nucleus (PVN) (see fig. 1).

The critical importance of both NPY/AgRP and POMC neurons in food intake and energy balance is highlighted by elegant conditional gene deletion experiments. Conditional deletion of AgRP neurons in the ARC was achieved by targeting the human diphtheria toxin to the AgRP locus. Adult mice were subsequently treated with diphtheria toxin to destroy AgRP neurons,
which resulted in a rapid reduction in food intake and body weight [1, 2]. Deletion of POMC neurons in adulthood produced a gradual increase in food intake and body weight [2]. Interestingly, AgRP-deleted mice without any intervention starved to the point of death [2], whereas POMC-deleted mice ‘only’ became obese [1]. These results imply a greater evolutionary selection pressure to maintain NPY/AgRP cell firing compared to POMC cell firing in the ARC. As a result, it is important to understand the mechanisms that control NPY and POMC cell function. One potential mechanism may be related to hormonal activation; for example, ghrelin induces NPY cell firing but not POMC cell firing. In this review, we examine recent advances in the neuroendocrine actions of ghrelin on hypothalamic food intake and body weight. We will specifically examine the mechanisms through which ghrelin maintains NPY/AgRP firing and suggest that the major role of ghrelin is to maintain hypothalamic energy and glucose homeostasis during negative energy balance and not positive energy balance. Indeed, our recent results show that diet-induced obesity (DIO) causes ghrelin resistance in arcuate NPY/AgRP neurons.

Ghrelin

Ghrelin is a 28-amino-acid orexigenic hormone that stimulates growth hormone release and enhances feeding and weight gain to regulate energy homeostasis [3]. These effects are mediated through activation of the growth hormone secretagogue receptor (GHSR), a 7-transmembrane G-protein-coupled receptor [4]. Pro-ghrelin mRNA is highly expressed in the stomach with lower levels also found in the duodenum, jejunum, ileum and colon [5, 6]. There is some evidence that ghrelin is also produced in the hypothalamic ARC, although the neurochemical phenotype of GHSR-containing neurons in the PVN is unknown. 3V = Third ventricle.
Ghrelin is acylated by the enzyme ghrelin O-acyltransferase (GOAT), a highly conserved member of the membrane-bound O-acyltransferase family of acyltransferases that attach fatty acids to lipids and proteins [8, 9]. As expected, the relative tissue distribution of GOAT mRNA matches that of ghrelin [9]; GOAT mRNA is highest in the stomach, but is also detectable in the small intestine, colon and pancreas [8, 9]. Dual-label histochemical analyses show that GOAT and ghrelin colocalize to the same cells within the stomach and duodenum [10]. In these cells, GOAT is localized to the endoplasmic reticulum [9], where pro-ghrelin is acylated. GOAT can acylate pro-ghrelin with other fatty acid substrates besides octanoate and this is likely a function of dietary fatty acid availability [11]. Once ghrelin is acylated with a medium-chain fatty acid, it is transported to the Golgi apparatus and cleaved by prohormone convertase 1/3 to form 28-amino-acid mature ghrelin [12]. The plasma des-acyl ghrelin levels are about fourfold higher than acyl ghrelin, suggesting that the des-acyl form of ghrelin is dominant in the blood [13], although the mechanisms that control the rate at which acyl-ghrelin becomes des-acylated are unknown.

Consistent with ghrelin’s well-characterized roles in regulating growth hormone function and energy homeostasis, the strongest expression of GHSR mRNA is in the hypothalamus [14] with highest expression in the ARC [15]. Here, the GHSR is expressed on growth hormone

![Diagram](image-url)
releasing hormone (GHRH)-expressing neurons [16, 17], tyrosine-hydroxylase-expressing neurons [15, 18] and NPY/AgRP neurons [17].

Ghrelin’s effects on food intake and energy homeostasis are largely mediated by arcuate NPY/AgRP neurons. In these neurons, ghrelin administration induces Fos-immunoreactivity [19–21], action potential firing [7, 19] and increased expression of NPY and AgRP mRNA [22–24]. Ghrelin does not stimulate feeding in mice that lack both NPY and AgRP [25, 26], confirming that NPY and AgRP neurons mediate ghrelin’s orexigenic actions (fig. 2).

The stimulatory effects of ghrelin on orexigenic NPY/AgRP neurons are complemented by reduced POMC neuronal activity via inhibitory γ-aminobutyric acid (GABA)-ergic inputs from NPY/AgRP neurons [7]. Ablation of AgRP neurons or AgRP neuron-specific deletion of vascular GABA transporter removes the inhibitory tone onto postsynaptic POMC cells, allowing unopposed activation of the melanocortin system and subsequent anorexia [27]. GABA-mediated electrophysiological inhibition of POMC neurons by NPY/AgRP neurons is accompanied by changes in POMC neuronal synaptic plasticity [19].

Mechanisms of Ghrelin’s Action on NPY Neurons

Because AgRP-ablated adult mice starved to death [2] and POMC-ablated adult mice ‘only’ became obese [1], we hypothesized that NPY/AgRP neurons evolved particular intracellular mechanisms to maintain firing under conditions of negative energy balance. One key endocrine signal may be ghrelin, as the GHSR is located on NPY/AgRP but not on most POMC neurons (<8%) [17] and ghrelin is increased in the plasma of fasted and calorie-restricted mice [3, 28, 29]. Not all studies show a consistent increase in plasma ghrelin in response to negative energy balance in rodents and humans [11, 30], which may be related to assay differences [31]. The difference between NPY/AgRP and POMC neurons may be related to ghrelin-induced intracellular activation of fatty acid oxidation pathways and reactive oxygen species (ROS) buffering in NPY/AgRP neurons but not POMC neurons [19, 32–34]. Ghrelin does not activate these pathways in POMC neurons, as most POMC neurons lack the GHSR [17]. Ghrelin activates AMP-activated kinase (AMPK) in the hypothalamus [33, 35] and specifically activates AMPK in NPY neurons via increased intracellular calcium [36]. AMPK is an intracellular energy sensor that switches off ATP-consuming pathways and switches on ATP-producing pathways such as glucose uptake and fatty acid oxidation [37]. Downstream actions of AMPK include phosphorylation of acetyl CoA carboxylase (ACC), which causes the suppression of malonyl CoA and dis inhibition of carnitine palmitoyl transferase 1 (CPT1). Increased CPT1 increases fatty acid acyl-CoA transport into mitochondria for oxidation. Indeed, both CPT1 and malonyl CoA play important roles in regulating food intake, as inhibition of CPT1 decreases food intake [38], as does activation of malonyl CoA [39]. Because ghrelin activates AMPK in NPY neurons, we hypothesized it would allow downstream activation of CPT1 to drive food intake. Ghrelin activates CPT1 (via AMPK) in the hypothalamus and CPT1 activation is required for ghrelin to stimulate food intake [19, 34]. Ghrelin also activates uncoupling protein-2 (UCP2)-dependent mitochondrial respiration, driven by the fatty acid oxidation of palmitate. UCP2 is required to permit CPT1 activation and subsequent mitochondrial-fatty-acid-driven respiration [19]. Furthermore, ghrelin initially increases the fatty acyl-CoA concentration in the hypothalamus as a substrate for fatty acid oxidation in mitochondria. We discovered that UCP2, specifically in NPY/AgRP neurons, is required to buffer excessive ROS production generated by ghrelin-induced fatty acid oxidation [19]. Thus, ghrelin activation of this AMPK-CPT1-UCP2 pathway permits increased fatty acid oxidation while buffering increased ROS in NPY neurons but not POMC neurons. This increase in mitochondrial activity and ROS buffering permits an increase in NPY and AgRP mRNA gene expression, sustained NPY/AgRP cell firing and elevated food intake. As such, we propose that the ability of ghrelin to activate the AMPK-CPT1-UCP2 pathway in NPY/AgRP neurons, but not POMC neurons, is the critical mechanism that allows sustained NPY/AgRP firing during starvation. This appears to be a selective advantage to maintain NPY/AgRP cell function especially considering that ablation of NPY/AgRP results in starvation and death, and ablation of POMC ‘only’ results in obesity.

It should be mentioned that ghrelin, GHSR and GOAT knockout mice show little or no obvious impairment in food intake and results from these studies suggest ghrelin’s major role is in glucose homeostasis [29, 40–43]. However, it is too early to dismiss an endogenous physiological role for ghrelin in food intake based solely on these knockout data. Indeed, initial NPY, AgRP and double NPY/AgRP knockouts also showed no obvious defect in food intake, suggesting compensatory mechanisms...
through development ensure food intake pathways are stable in adulthood despite the lack of NPY, AgRP or both NPY and AgRP. A similar mechanism may be occurring in the ghrelin, GHSR and GOAT knockouts.

Intriguingly, we observed increased ROS production in POMC neurons compared to NPY neurons under basal conditions, suggesting POMC neurons might be prone to free-radical-induced degeneration over time [19]. The decline in functional POMC neurons over time may promote increased orexigenic NPY tone and lead to hyperphagia and weight gain associated with ageing.

DIO Causes Ghrelin Resistance in NPY/AgRP Neurons

The studies above highlight the mechanism through which ghrelin promotes NPY/AgRP neuronal firing. However, little is known about how ghrelin affects NPY/AgRP function during DIO, which is important as several components of the neuroendocrine ghrelin system are disturbed by DIO. Firstly, peripherally administered ghrelin does not stimulate food intake in mice fed a high-fat diet (HFD) for 16 weeks [44]. Secondly, DIO impairs the transport of ghrelin across the blood-brain barrier [45]. Lower circulating ghrelin in conjunction with impaired transport into the brain results in less ghrelin signal at the level of GHSR-containing neurons. Thirdly, DIO causes disruption of hypothalamic appetite-regulating circuits, as mice bred to develop DIO have reduced density of NPY/AgRP and POMC axons innervating the PVN [46]. Fourthly, DIO suppresses the basal AMPK activity in the hypothalamus, although this suppression is only significant in the PVN [47, 48]. Taken together, these data suggest the ghrelin-AMPK-NPY/AgRP system is impaired by DIO. This led us to hypothesize that (1) the hypothalamic circuitry controlling food intake becomes resistant to ghrelin during obesity, and (2) that ghrelin resistance is a centrally mediated phenomenon, which alters NPY/AgRP circuits.

We recently demonstrated that DIO suppresses the neuroendocrine ghrelin system and causes ghrelin resistance in ARC neurons [49]. In DIO mice, ghrelin and GOAT mRNA in the stomach and plasma ghrelin are all decreased [49, 50]. Reduced circulating ghrelin in DIO mice is compounded by decreased expression of hypothalamic GHSR [49]. The GHSR has high constitutive activity [51] and contributes to the basal regulation of food intake and body weight even in the absence of ghrelin ligand binding [52]. Thus, decreased hypothalamic GHSR mRNA expression may further contribute to hypothalamic ghrelin resistance due to lower basal constitutive activity [51] and less GHSR, to which ghrelin can bind (fig. 3).

In DIO mice, central ghrelin neither induces activation of ARC neurons as demonstrated by Fos immunoreactivity, nor increases expression of hypothalamic NPY and AgRP mRNA nor induces feeding in either the light or dark phases [49] (fig. 3). Ghrelin administration increases NPY activity in ex vivo hypothalamic slices from chow-fed mice, likely increasing the release of NPY and AgRP at nerve terminals in the PVN [7]. We showed that ghrelin does not induce AgRP or NPY peptide secretion in hypothalamic explants from DIO mice compared to chow-fed controls [49]. To determine whether downstream NPY/AgRP neural targets are intact, we delivered NPY directly into the lateral ventricle and this was able to induce food intake in both chow-fed and DIO mice. Thus, in DIO mice, ghrelin resistance in NPY/AgRP neurons is the result of decreased NPY/AgRP peptide release at synaptic targets in the PVN. Collectively, our data demonstrate that central hypothalamic ghrelin resistance is a product of two presumably dependent mechanisms. First, DIO suppresses the neuroendocrine ghrelin axis and second, DIO impairs NPY/AgRP neuronal function in the ARC of the hypothalamus and reduces responsiveness to ghrelin. The exact hypothalamic mechanisms behind this phenomenon are unclear but may be related to endocrine changes that occur in DIO such hyperglycemia and hyperinsulinemia. Central infusion of insulin during fasting prevents upregulation of NPY mRNA expression and reduces immunoreactive NPY concentrations in the PVN [53]. Central insulin infusion also reduces both hyperphagia and overexpression of hypothalamic NPY mRNA in diabetic rats [47]. Central insulin infusion does not affect plasma insulin, indicating that insulin acts locally to inhibit hypothalamic NPY mRNA expression. These effects may be mediated by reduced AMPK activity in ARC NPY/AgRP neurons, as central infusion of glucose or insulin inhibits the activity of α2AMPK activity in the ARC and PVN [54]. Knockdown of α1 and α2 AMPK subunits decreases expression of NPY and AgRP mRNA, resulting in reduced feeding and weight loss [54]. Finally, peripheral infusion of glucose, free fatty acids or insulin during eu-glycemia suppresses plasma ghrelin, but importantly, these effects are mediated by insulin [55, 56]. Collectively, these data suggest that glucose and insulin are important negative regulators of ghrelin in the plasma and ghrelin activation of NPY/AgRP firing. Future studies are required to prove that hyperglycemia and hyperinsu-
Metabolic Status and Ghrelin Function Neuroendocrinology 2011;93:48–57 53

Linemia in DIO cause ghrelin resistance in NPY/AgRP neurons.

Interestingly, central ghrelin increases plasma growth hormone in chow-fed mice but not in DIO mice [49]. This supports our hypothesis that DIO promotes hypothalamic ghrelin resistance, and further that hypothalamic ghrelin resistance is not only confined to appetite-regulating pathways but also affects other neurons expressing GHSR. As ghrelin was injected intracerebroventricularly, we believe ghrelin does not activate GHRH neurons in the ARC in DIO, although this requires experimental proof. Further, DIO decreases in pituitary GHSR expression [57], showing that DIO reduces ghrelin-induced growth hormone release at both the hypothalamic and pituitary levels.
Theander-Carrillo et al. [58] showed that chronic central ghrelin increases fat deposition independently of changes in food intake, as shown by pair-feeding experiments. Central ghrelin increased the respiratory quotient, indicating greater carbohydrate metabolism, without alterations in total energy expenditure or spontaneous physical activity. Central ghrelin increased the white adipose tissue mRNA levels of the fat-storage-promoting enzymes lipoprotein lipase (LPL), ACCα, fatty acid synthase and stearoyl-CoA desaturase-1 in both ad libitum and pair-fed animals.

The effect of ghrelin on adiposity is independent of ghrelin-induced feeding mediated by NPY/AgRP peptide release, as NPY-induced food intake only increases body weight in ad-libitum-fed mice but not pair-fed mice [59]. In addition, ghrelin increases body weight in NPY-deficient mice [60], indicating that NPY activation in the ARC is not involved in ghrelin-induced fat accumulation.

Thus, ghrelin’s effect on body weight and adiposity is not mediated by ghrelin-induced NPY activity in the ARC and subsequent NPY-induced food intake. These body weight effects are presumably mediated by additional hypothalamic nuclei.

The PVN is a candidate hypothalamic nucleus that regulates ghrelin-induced weight gain. GHSR is expressed in the PVN [15], indicating that ghrelin directly activates these neurons. Recent studies examined the role of ghrelin in the PVN by selectively knocking down GHSRs in vivo (60% knockdown) using RNA interference. GHSR knockdown does not affect daily food intake but significantly reduces body weight and blood ghrelin levels [61]. Thus, direct ghrelin activation of GHSR in the PVN regulates body weight independently of food intake. Further, central ghrelin injection in DIO mice activates Fos-positive neurons in the PVN, even though ARC neurons are not activated [49] (fig. 4). In DIO conditions, we hypothesize that ghrelin increases adiposity through PVN signaling despite ghrelin resistance in the ARC. Therefore, we suggest that the PVN is presumably both a ‘first-order’ and ‘second-order’ nucleus responding directly to ghrelin that has gained access in the cerebrospinal fluid (first order) and responding indirectly to ghrelin-induced NPY and AgRP release (second order). Collectively, these data demonstrate that central ghrelin increases energy partitioning and regulates adipocyte metabolism, independently of ghrelin’s actions on NPY neurons.

The hypothalamic actions of ghrelin in energy metabolism are twofold: (1) ghrelin acts via NPY/AgRP neurons in the ARC to increase food intake and (2) ghrelin acts directly on GHSR-containing neurons in the PVN to increase body weight and adiposity. Further studies are required to elucidate the different functions of GHSR signaling in different hypothalamic nuclei.

Ghrelin Is Critical for Survival under Calorie Restriction – Insights from Knockout Studies

Despite the importance of the ghrelin system in regulating food intake and body weight, mice lacking ghrelin, GOAT or GHSR show no, or only a modest, metabolic phenotype [18, 29, 42, 62–65]. Under conditions of standard laboratory housing these mice have normal life span and food intake. Slight differences in body weight have been observed in some but not all cases. Studies show that GHSR<sup>−/−</sup> mice but not ghrelin<sup>−/−</sup> mice have significantly reduced body weight on a regular chow diet [42, 65], and this difference may be related to the consti-
tutive signaling properties of the GHSR in the absence of ligand binding [52]. However, using a different GHSR−/− mouse line, Zigman et al. [64] did not witness any difference in body weight on a standard chow diet. Moreover, Pflüger et al. [66] only found a significant difference in body weight when ghrelin−/− or GHSR−/− mice were bred together to generate double-knockout mice.

Modest changes are observed when ghrelin−/− and GHSR−/− mice are subjected to an HFD [42, 63, 64]. Ghrelin−/− mice gain less weight and had greater energy expenditure on an HFD than their wild-type controls despite having the same food intake [62]. However, recent studies using congenic ghrelin−/− mice outbred on a C57/B6 (n = 10) background showed no protection against HFD [42]. GHSR−/− mice also gain less weight on HFD, and are slightly hypophagic [64], although Sun et al. [42] observed a reduction in body weight gain in GHSR−/− mice relative to wild-type mice on HFD in the absence of hypophagia or differences in energy expenditure. The equivocal results on body weight from knockout animals on either standard chow or HFD might be related to strain differences.

Studies from knockout mice illustrate that the major role of ghrelin is not to regulate food intake or body weight but rather to regulate glucose homeostasis. Ablation of ghrelin in ob/ob mice fails to reduce hyperphagia and body weight but decreases hyperglycemia and improves peripheral insulin sensitivity [41]. Deletion of the GHSR markedly reduces blood glucose and plasma insulin upon fasting, suggesting that GHSR deletion increases insulin sensitivity [42]. This is in accordance with clinical studies showing that low plasma ghrelin is associated with insulin resistance [67–69].

Under 50–60% calorie restriction mice lacking ghrelin, GHSR and GOAT have lower blood glucose levels than their wild-type littermates [29, 42]. Recent studies in GOAT−/− mice, the enzyme that acylates pro-ghrelin, show that an essential function of ghrelin is to maintain survival during severe calorie restriction [29]. These mice lacked acylated ghrelin and could not control blood glucose during severe calorie restriction. After 7–8 days of calorie restriction the mice appeared moribund and had to be euthanized. Infusion of ghrelin or growth hormone normalized blood glucose to wild-type levels. Interestingly, GOAT−/− mice showed no defect in food intake under normal dietary or calorie-restricted conditions. These studies clearly illustrate that ghrelin is required to maintain survival under conditions of severe negative energy balance, not by increasing food intake but rather by maintaining blood glucose. In support of this notion, the fast-
ed blood glucose levels are not different in GHSR−/− mice on an HFD but are lower in calorie-restricted GHSR−/− mice compared to wild-type controls [42]. Our hypothesis is supported by increased plasma ghrelin during negative energy balance. Since the neuroendocrine ghrelin system is suppressed in DIO, we postulate that ghrelin does not play a major role in the pathogenesis of diabetes.

Current ghrelin, GHSR and GOAT knockout models suggest that ghrelin plays a minimal role in food intake and body weight, despite the wealth of literature showing that exogenous ghrelin administration increases food intake and adiposity. However, it is too early to dismiss a role for ghrelin in food intake and body weight based on these knockout models. An important development to understand the true physiological role of ghrelin will be the generation of a temporal ghrelin knockout mouse. This transgenic mouse line will sidestep the issue of compensatory developmental mechanisms that may ensure food intake and body weight gain after ghrelin deletion. This is important as neonatal ablation of NPY/AgRP neurons has minimal effects on feeding, whereas ablation in adults causes rapid starvation [2].

Conclusions

The research highlighted above now points towards ghrelin as a key modulator of energy metabolism during negative energy balance and starvation. Most notably, knockout models show that ghrelin is indispensable for blood glucose control during starvation. Whether or not ghrelin plays a role in the pathogenesis of diabetes, by promoting hyperglycemia, remains to be determined. In DIO, the actions of ghrelin to increase food intake in the brain are suppressed at the level of the hypothalamic ARC nucleus. Furthermore, ghrelin peptide in the circulation, as well as ghrelin and GOAT mRNA in the stomach and GHSR in the hypothalamus are all reduced. These observations further support the important role of ghrelin in negative energy balance, rather than positive energy balance, i.e. obesity. Future research is required to determine whether ghrelin resistance occurs in other regions of the brain that express the GHSR.

Acknowledgements

This work was supported by a Monash Fellowship, Monash University, Australia; Monash University Strategic Grant Scheme – Early Career Development Award and NHMRC grant (NHMRC 546131) to Z.B.A.

Metabolic Status and Ghrelin Function
References


Metabolic Status and Ghrelin Function


56 McCowan KC, Maykel JA, Bistrian BR, Ling PP: Circulating ghrelin concentrations are lowered by intravenous glucose or hyperinsulinemia of eating behavior and energy expenditure. Am J Physiol Gastrointest Liver Physiol 2008; 294:G610–G618.


Metabolic Status and Ghrelin Function

Neuroendocrinology 2011;93:48–57